Novartis Invests Via Its Venture Capital Arm

Multinational drugmaker Novartis has signed an agreement withHeptares Therapeutics, a drug discovery company focused on G-protein-coupled receptor (GPCR) targets. As a part of the agreement, Heptares will apply its proprietary StaR(TM) technology to generate novel drug leads against a nominated, unspecified GPCR target of interest to Novartis. The agreement includes upfront and potential milestone payments to Heptares totalling up to US$200mn, plus royalties.

To read the full article, please sign in or take a free trial.